Seres Therapeutics Inc (MCRB) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Seres Therapeutics Inc $9.64, price $3.62, upside +166.3%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Seres Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $3.62 – $487.20 · fair‑value band $4.24 – $13.88 · the $3.62 price screens below the $9.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Seres Therapeutics in your weekly email
Every Wednesday you see whether Seres Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases.
Show more
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Stock analysis
Seres Therapeutics Inc (MCRB) currently trades at $3.62, while our model-based Fair Value estimate is $9.64, implying the stock looks roughly 62.4% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $26.35 per share, and 10 of the 12 models we run sit above the $3.62 price.
Bear case: the Asset-Based group reads lowest at $2.95, and 2 of the 12 models stay below the price. Evidence for this calculation is low.
Scenario range: $4.24 (bear) to $13.88 (bull), the price of $3.62 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Seres Therapeutics Inc reported revenue of $789K in FY2025 versus $145M in FY2021, a compound −72.8%/yr. Reported net income was $5.7M in FY2025.
Key figures
Market cap $42.3M · P/S ratio 22.5 · EPS (TTM) $−2.42 · Return on equity −66.6% · Return on assets (EBIT) −55.8% · Operating margin −2,101% · Revenue (TTM) $1.9M · Revenue growth (YoY) −93.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 87% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 166%, MCRB screens cheaper than that median.
Fair Value models
Bear $4.24Fair Value $9.64Bull $13.88
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−52.7%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−30.8%
’16
’17
’18
’19
’20
’21
’23
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−265.3% (2020) → −11,910.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+37.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +34.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Below median
Fair Value upside+166% · Top 25%
Profitability
Return on assets−40% · Bottom 25%
Growth and dividend
Revenue growth−93% · Bottom 25%
Balance sheet
Debt / equity2.30× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Seres Therapeutics Inc (MCRB) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $9.64 versus a price of $3.62, about +166% upside (undervalued).
What is the fair value of MCRB?
Our model-based fair value for Seres Therapeutics Inc is $9.64 (as of Sep 24, 2026), built from audited fundamentals. The current price: $3.62.
What is the quality score of MCRB?
Seres Therapeutics Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Seres Therapeutics Inc (MCRB)?
Our model-based price target is the fair value of $9.64 (as of Sep 24, 2026) from 12 valuation models. Cautious scenario $4.24, optimistic scenario $13.88. It is a calculation from audited fundamentals, not an analyst target.
What is the Seres Therapeutics Inc stock forecast for 2026?
Our models put fair value at $9.64, about +166% upside versus a price of $3.62 (undervalued). Cautious scenario $4.24, optimistic scenario $13.88. The calculation is refreshed regularly with new filings.
What is the revenue of Seres Therapeutics Inc (MCRB)?
Seres Therapeutics Inc reported trailing-twelve-month revenue of about $1.9M (latest available figure, as of Sep 24, 2026).
What growth is priced into Seres Therapeutics Inc (MCRB)?
For today's price to be fair in a discounted-cash-flow model, Seres Therapeutics Inc would have to grow free cash flow by +37.8 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -52.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of MCRB use?
Our models discount Seres Therapeutics Inc at 8.5 %: a base by market capitalisation (nano), damped by beta 0.22, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Seres Therapeutics Inc that is +37.8 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Seres Therapeutics Inc (MCRB) delivered so far?
Over the past 5 years revenue at Seres Therapeutics Inc grew -52.7 % a year. The price currently implies +37.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Seres Therapeutics Inc (MCRB) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Seres Therapeutics Inc (+37.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Seres Therapeutics Inc (MCRB)?
The free-cash-flow yield on the price is 2.48 %: that much free cash flow Seres Therapeutics Inc produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Seres Therapeutics Inc (MCRB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Seres Therapeutics Inc it is $9.64 per share (as of Sep 24, 2026), against a price of $3.62. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Seres Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MCRB trades below its calculated fair value: price $3.62, fair value $9.64, a gap of about +166% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MCRB?
No. The price is what the market pays today ($3.62); the fair value is what the company's own numbers justify ($9.64). For Seres Therapeutics Inc the two are $6.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Seres Therapeutics Inc worth?
The market values Seres Therapeutics Inc at about $42.3M (market capitalisation, as of Sep 24, 2026). Per share that is $3.62; our models calculate a fair value of $9.64 per share.
What do the bullish and bearish scenarios say about MCRB?
Our models span a range for Seres Therapeutics Inc: cautious scenario $4.24, base $9.64, optimistic $13.88 per share (as of Sep 24, 2026, price $3.62). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Seres Therapeutics Inc (MCRB)?
Balance-sheet figures for Seres Therapeutics Inc (as of Sep 24, 2026): return on equity −66.6%, debt of 2.30 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is MCRB from its 52-week high?
Seres Therapeutics Inc trades at $3.62, about 87% below its 52-week high of $28.63 and at the low of $3.62 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $9.64 is for.
Which stocks are comparable to Seres Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Seres Therapeutics Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $3.62, calculated fair value $9.64 (+166%), Quality Score 37/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MCRB calculated?
We run Seres Therapeutics Inc through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $9.64, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Seres Therapeutics Inc currently trades 166 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Seres Therapeutics Inc (MCRB)?
The closing price on Sep 24, 2026 was $3.62. Our model-based fair value is $9.64, about +166% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Seres Therapeutics Inc right now?
The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($4.24). The market is more pessimistic than our downside scenario. The model range is unusually wide ($4.24 to $13.88). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Seres Therapeutics Inc
How large is the market capitalisation of Seres Therapeutics Inc (MCRB)?
The market capitalisation of Seres Therapeutics Inc is $42.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Seres Therapeutics Inc (MCRB)?
The price-to-sales ratio of Seres Therapeutics Inc is 22.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Seres Therapeutics Inc (MCRB)?
Earnings per share at Seres Therapeutics Inc are $−2.42. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Seres Therapeutics Inc (MCRB)?
The return on equity (ROE) of Seres Therapeutics Inc is −66.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Seres Therapeutics Inc (MCRB)?
On an EBIT basis the return on assets of Seres Therapeutics Inc is −55.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Seres Therapeutics Inc (MCRB)?
The operating margin of Seres Therapeutics Inc is −2,101% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Seres Therapeutics Inc (MCRB)?
Revenue at Seres Therapeutics Inc is growing −93.4% versus a year earlier (3y avg −52.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Seres Therapeutics Inc (MCRB)?
Earnings per share at Seres Therapeutics Inc are growing −91.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Seres Therapeutics Inc (MCRB) carry?
The net debt of Seres Therapeutics Inc is $37.2M (fiscal year 2025, ≈ 43.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Seres Therapeutics Inc in the live analysis
One click puts Seres Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026